| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/13/2000 | WO2000040227A2 Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| 07/13/2000 | WO2000040226A2 Method of treating sexual disturbances |
| 07/13/2000 | WO2000040215A1 Cosmetic or dermatological composition containing an active principle stimulating hsp 32 protein synthesis in the skin and cosmetic treatment method |
| 07/13/2000 | WO2000040172A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | WO2000040089A1 Targeted transscleral controlled release drug delivery to the retina and choroid |
| 07/13/2000 | WO2000040088A1 Amide derivatives for antiangiogenic and/or antitumorigenic use |
| 07/13/2000 | WO2000040086A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | WO2000027363B1 Aerosols comprising nanoparticle drugs |
| 07/13/2000 | WO2000025764A3 Compositions for the treatment and prevention of cardiovascular diseases |
| 07/13/2000 | WO2000023091A3 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| 07/13/2000 | WO2000022121A3 Ion channels, in particular vanilloid receptor-like (vr-l) receptor |
| 07/13/2000 | WO2000021987A3 A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease |
| 07/13/2000 | WO2000019976A3 Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them |
| 07/13/2000 | WO2000018801A3 Ncam binding compounds |
| 07/13/2000 | WO2000015208A3 New use of immunosupressants for mmp-mediated diseases |
| 07/13/2000 | WO2000015207B1 Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) |
| 07/13/2000 | WO2000015175A3 Use as an active substance of molecules binding to beta-1-integrin with the capacity to kill cells |
| 07/13/2000 | WO2000010582A3 Probiotic, lactic acid-producing bacteria and uses thereof |
| 07/13/2000 | WO2000006597A9 Endogenous constitutively activated g protein-coupled orphan receptors |
| 07/13/2000 | WO2000006534A9 Compounds and compositions for delivering active agents |
| 07/13/2000 | WO2000003737A9 Water-soluble drugs and methods for their production |
| 07/13/2000 | DE19900674A1 Bindungspartner für 5-HT5-Rezeptoren zur Migränebehandlung Binding partners for 5-HT5 receptors in migraine treatment |
| 07/13/2000 | DE19900673A1 Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders |
| 07/13/2000 | CA2360396A1 Characterization of a calcium channel family |
| 07/13/2000 | CA2358851A1 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 07/13/2000 | CA2358754A1 Synergistic tumorcidal response induced by histamine |
| 07/13/2000 | CA2358491A1 Antitumor agents |
| 07/13/2000 | CA2358438A1 Antiviral method using mek inhibitors |
| 07/13/2000 | CA2358430A1 Potentiation of anti-cd38-immunotoxin cytotoxicity |
| 07/13/2000 | CA2358296A1 Targeted transscleral controlled release drug delivery to the retina and choroid |
| 07/13/2000 | CA2358212A1 Formulations for treating disease and methods of using same |
| 07/13/2000 | CA2357146A1 Human cyclic nucleotide pdes |
| 07/13/2000 | CA2356434A1 Non-myeloablative tolerogenic treatment |
| 07/13/2000 | CA2356368A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents |
| 07/13/2000 | CA2350946A1 Method of treating sexual disturbances |
| 07/13/2000 | CA2350234A1 Treatment of asthma with mek inhibitors |
| 07/12/2000 | EP1018517A2 Binding agents to CD23 for treatment of inflammatory, autoimmune or allergic diseases |
| 07/12/2000 | EP1018420A1 Plastic screw cap and method for manufacturing the same |
| 07/12/2000 | EP1017980A2 Methods of the identification of pharmaceutically active compounds |
| 07/12/2000 | EP1017854A1 Documentation means for repertoires of nkr immunoreceptors and/or activatory or non-inhibitory immunoreceptor counterparts of nkr immnunoreceptors |
| 07/12/2000 | EP1017846A1 Control of immune responses by modulating activity of glycosyltransferases |
| 07/12/2000 | EP1017835A1 Methods of using cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy |
| 07/12/2000 | EP1017826A2 Compositions and methods for identifying pkb kinase inhibitors |
| 07/12/2000 | EP1017823A2 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 07/12/2000 | EP1017810A1 Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| 07/12/2000 | EP1017723A2 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use |
| 07/12/2000 | EP1017720A1 Site-directed chemotherapy of metastases |
| 07/12/2000 | EP1017414A1 Therapeutic method for management of diabetes mellitus |
| 07/12/2000 | EP1017412A1 Genes coding proteins for early liver development and their use in diagnosing and treating liver disease |
| 07/12/2000 | EP1017410A1 Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
| 07/12/2000 | EP1017408A1 Use of gastrointestinal lipase inhibitors |
| 07/12/2000 | EP1017402A1 Control of acidic gut syndrome |
| 07/12/2000 | EP1017401A2 Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid a |
| 07/12/2000 | EP1017400A1 Method of treatment |
| 07/12/2000 | EP1017398A1 Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| 07/12/2000 | EP1017397A1 Photosensitizer conjugates for pathogen targeting |
| 07/12/2000 | EP1017395A1 Method for treating premenstrual or late luteal phase syndrome |
| 07/12/2000 | EP1017390A2 Combinations of hmg-coa inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
| 07/12/2000 | EP1017389A1 Prevention of adhesions and excessive scar formation using angiogenesis inhibitors |
| 07/12/2000 | EP1017380A1 Topical non-steroidal anti-inflammatory drug composition |
| 07/12/2000 | EP1017376A1 Method of treating heart failure |
| 07/12/2000 | EP1017375A2 Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| 07/12/2000 | EP1017370A1 MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs) |
| 07/12/2000 | EP1017367A1 Methods for fabricating polymer-based controlled release preparions |
| 07/12/2000 | EP1017366A1 Solid coprecipitates for enhanced bioavailability of lipophilic substances |
| 07/12/2000 | EP1017363A1 Taste masking for unpalatable formulations |
| 07/12/2000 | EP0918545B1 Tumour therapy |
| 07/12/2000 | EP0900007A4 Low ph acidic compositions |
| 07/12/2000 | EP0633767B1 Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| 07/12/2000 | CN1259875A Pharmaceutical compositions contg. anti-body-enzyme conjugates in combination with prodrugs |
| 07/12/2000 | CN1259868A Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for treating cancer |
| 07/12/2000 | CN1259866A Therapeutic treatment for skin disorders |
| 07/12/2000 | CN1259863A Therapeutically active compositions |
| 07/12/2000 | CN1259522A Novel protain from lobar pneumonia Actinomyces |
| 07/11/2000 | US6087489 Antisense oligonucleotide modulation of human thymidylate synthase expression |
| 07/11/2000 | US6087479 Introducing into patient a medical device of which at least a portion includes a nitric oxide adduct which may be a sodium nitroprusside, a nitrosothiol, a nitrate, a nitrite or a nitrosated amino acid |
| 07/11/2000 | US6087477 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 07/11/2000 | US6087394 Compositions, apparatus and methods for facilitating surgical procedures |
| 07/11/2000 | US6087356 Anesthetizing the patient to produce a state of unconsciousness, administering dextromethorphan to reduce the feelings of withdrawal symptoms, administering an opioid antagonist to induce acute withdrawal |
| 07/11/2000 | US6087352 Administering to a female horses and pigs, to control the estrous cycle so that the timing of fertility may be selected |
| 07/11/2000 | US6087351 Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone |
| 07/11/2000 | US6087350 Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
| 07/11/2000 | US6087344 A pharmaceutical composition for effective drug delivery through skin or exposed tissue of a human |
| 07/11/2000 | US6087169 HKABY60: polynucleotide encoding a helix-loop-helix ubiquitous kinase family polypeptide |
| 07/11/2000 | US6087142 Valyl tRNA synthetase from streptococcus pneumoniae |
| 07/11/2000 | US6087122 Polynucleotide sequence which codes a mammalian polypeptide synthetases; for diagnosis, evaluation, prevention, and treatment of physiological defects |
| 07/11/2000 | US6087110 Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| 07/11/2000 | US6087092 Dietary fiber and a polyphenol compound which efficiently reduces diarrhea in human and other animals |
| 07/11/2000 | US6086914 Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| 07/11/2000 | US6086909 Device and method for treatment of dysmenorrhea |
| 07/11/2000 | US6086898 Administering listeria adjuvants and antigens for immunology |
| 07/11/2000 | US6086874 Kit comprising an interleukin-6 (il-6) antagonist such as antibody to il-6, antibody to il-6 receptor, and antibody to gp130 protein, an antitumor agent such as cisplatin, and a carrier; antagonist and antitumor agent not physically bonded |
| 07/11/2000 | US6085754 Cardiac disease treatment method |
| 07/11/2000 | CA1341048C Method and compositions for making acsf and acsf antagonists |
| 07/06/2000 | WO2000039589A1 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists |
| 07/06/2000 | WO2000039588A1 Detection of preactivated phagocytes |
| 07/06/2000 | WO2000039314A1 ASSAY FOR IDENTIFYING COMPOUNDS WHICH AFFECT STABILITY OF mRNA |
| 07/06/2000 | WO2000039308A1 Ikk3 kinase |
| 07/06/2000 | WO2000039287A2 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides and uses thereof |
| 07/06/2000 | WO2000039283A1 Use of cd40 engagement to alter t cell receptor usage |